
==== Front
Gut Microbes
Gut Microbes
Gut Microbes
1949-0976
1949-0984
Taylor & Francis

39312647
10.1080/19490976.2024.2400575
2400575
Version of Record
Research Article
Research Paper
EspH utilizes phosphoinositide and Rab binding domains to interact with plasma membrane infection sites and Rab GTPases*
I. NANDI ET AL.
GUT MICROBES
https://orcid.org/0000-0002-4502-2559
Nandi Ipsita a b
https://orcid.org/0000-0002-4448-5906
Ramachandran Rachana Pattani a b
https://orcid.org/0000-0003-1100-785X
Shalev Deborah E. c d
https://orcid.org/0000-0003-0480-0438
Schneidman-Duhovny Dina e
https://orcid.org/0000-0002-3512-2062
Shtuhin-Rahav Raisa a b
https://orcid.org/0000-0001-9528-5026
Melamed-Book Naomi f
https://orcid.org/0000-0002-1396-3573
Zlotkin-Rivkin Efrat a b
https://orcid.org/0000-0002-9917-7564
Rouvinski Alexander g
https://orcid.org/0000-0001-7396-3586
Rosenshine Ilan g
https://orcid.org/0000-0003-2023-7913
Aroeti Benjamin a b
a Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, The Edmond J. Safra Campus – Givat Ram , Jerusalem, Israel
b Department of Cell and Developmental Biology, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, The Edmond J. Safra Campus – Givat Ram , Jerusalem, Israel
c The Wolfson Centre for Applied Structural Biology, The Hebrew University of Jerusalem, The Edmond J. Safra Campus – Givat Ram , Jerusalem, Israel
d The Department of Pharmaceutical Engineering, Azrieli College of Engineering , Jerusalem, Israel
e The Rachel and Selim Benin School of Computer Science and Engineering, The Hebrew University of Jerusalem , Jerusalem, Israel
f Bioimaging Unit, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem , Jerusalem, Israel
g Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University-Hadassah Medical School, of Jerusalem , Jerusalem, Israel
CONTACT Benjamin Aroeti aroeti@mail.huji.ac.il Department of Cell and Developmental Biology, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, The Edmond J. Safra Campus – Givat Ram, Jerusalem 9190401, Israel
23 9 2024
2024
23 9 2024
16 1 2400575Integra21 9 2024
Integra21 9 2024
02 7 2024
13 8 2024
15 8 2024
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

ABSTRACT

Enteropathogenic E. coli (EPEC) is a Gram-negative bacterial pathogen that causes persistent diarrhea. Upon attachment to the apical plasma membrane of the intestinal epithelium, the pathogen translocates virulence proteins called effectors into the infected cells. These effectors hijack numerous host processes for the pathogen’s benefit. Therefore, studying the mechanisms underlying their action is crucial for a better understanding of the disease. We show that translocated EspH interacts with multiple host Rab GTPases. AlphaFold predictions and site-directed mutagenesis identified glutamic acid and lysine at positions 37 and 41 as Rab interacting residues in EspH. Mutating these sites abolished the ability of EspH to inhibit Akt and mTORC1 signaling, lysosomal exocytosis, and bacterial invasion. Knocking out the endogenous Rab8a gene expression highlighted the involvement of Rab8a in Akt/mTORC1 signaling and lysosomal exocytosis. A phosphoinositide binding domain with a critical tyrosine was identified in EspH. Mutating the tyrosine abolished the localization of EspH at infection sites and its capacity to interact with the Rabs. Our data suggest novel EspH-dependent mechanisms that elicit immune signaling and membrane trafficking during EPEC infection.

KEYWORDS

Enteropathogenic e. coli
type III secreted effectors
EspH
Rab GTPases
Rho GTPases
phosphoinositides (PIs)
phosphoinositide binding domain (PBD) PI3K/Akt/mTORC1 signaling
lysosomal exocytosis
bacterial invasion
host-pathogen interactions
Israel Science Foundation 10.13039/501100003977 1671/19 RRS and IN are the recipients of Dr. Willem Been Legacy Fellowship. This research was supported by the Israel Science Foundation [grant No. 1671/19].
==== Body
pmcIntroduction

The human gastrointestinal pathogens, enteropathogenic and enterohemorrhagic Escherichia coli (EPEC and EHEC), are food or water-borne bacterial pathogens that continue to pose a significant threat to human health worldwide.1–3 Citrobacter rodentium is a natural murine intestinal pathogen that shares a set of virulence factors with EPEC and EHEC.4 The type III secretion system (T3SS), which has a syringe-like molecular structure, is a major virulence factor of these pathogens.5 They utilize it to inject dozens of proteins, termed effectors, from the bacterial cytoplasm into the host enterocytes. The coordinated activity of these effectors in space and time subverts numerous host cell processes and organelles to support successful bacterial colonization of the intestinal mucosa.6 A prominent hallmark of the infection is the appearance of the so-called “attaching and effacing” (A/E) lesions in the mucosal tissue. A/E lesions are characterized by intimate microbial attachment to the apical cell plasma membrane of the epithelial cells, local elimination of brush-border microvilli, and the formation of a filamentous (F)-actin-rich pedestal-like structure on top of which the bacterium resides. Studies suggest that the A/E pedestal formation contributes to bacterial pathogenesis.7 Injected effectors also contribute to bacterial colonization and pathogenesis by hijacking and subverting host cell signaling and membrane trafficking pathways, targeting various organelles, and modulating cell death and innate immunity.8–10 One such effector is EspH.

EspH is essential for virulence and is a multifunctional effector.11,12 It regulates the actin cytoskeleton and pedestal formation,13 conferring Rho GTPase14–18 and MAP kinase19 inhibition, inducing host cell cytotoxicity,15,17 inhibiting bacterial invasion (phagocytosis),12,16,17 and increasing cell death due to mitochondrial fragmentation.20 Following translocation into the host cell, EspH localizes at plasma membrane infection sites.15,17,19 Despite this knowledge, the molecular mechanisms underlying EspH’s activities are not fully understood. In this context, EspH has been recently shown to interact with the host active Bcr-related (ABR) protein to suppress the host RhoGTPases, Rac1 and Cdc42.17 These interactions, mediated by the effector protein’s C-terminal 38 amino acid segment (domain), are required for EspH-mediated inhibition of bacterial invasion and filopodia formation at infection sites and EspH-evoked host cell cytotoxicity.17

Rab GTPases constitute the largest subfamily of the Ras-related GTPase superfamily, regulating multiple steps in vesicular trafficking in eukaryotic cells.21–23 Like all members of the GTPase superfamily, Rabs can bind GDP (guanosine-5’-diphosphate) in the “off-state” or GTP (guanosine-5’-triphosphate) in the “on-state.” Host proteins that regulate cycling between the two states are guanine nucleotide exchange factors (GEFs) that catalyze the GDP-GTP exchange reaction and GTPase activating proteins (GAPs) that facilitate the hydrolysis of bound GTP, thereby switching the Rabs on and off, respectively,24 and targeting them to distinct cellular compartments.25 Switching between the active and inactive forms is characterized by conformational changes of two critical regions within the GTPases, called switch I and II.26 The Rab proteins also interact with an additional group of host proteins called “effector” proteins. These proteins bind with high affinity to the switch regions of Rab’s active form,27,28 exerting specific cellular functions, some of which are overridden by intracellular bacterial pathogens.29,30

Studies have shown that human bacterial pathogens (e.g., Salmonella enterica, Legionella pneumophila, Shigella flexneri, Listeria monocytogenes) target Rab GTPases to establish a replication niche that enables their survival within the host cells.30–32 Moreover, studies have indicated that type III secreted effectors can target host Rab GTPases directly.33–37 Salmonella’s SopD and Legionella’s LidA are, perhaps, the best-studied examples, as crystal structures with their Rab cognates have been resolved.38–40 SopD binds and displays a GAP activity that inhibits Rab8a,40,41 and Rab10.37 Effector proteins can also act as GEFs. For example, the Legionella’s SidM (DrrA) effector recruits and activates Rab1 via its GEF domain. The same effector also acts as a GDP dissociation inhibitor displacement factor of Rab1.42–44 Effector proteins can modulate the activity of Rabs by covalently modifying them. For example, the AMPylation activity of the Legionella SidM/DrrA modifies Rab1 by covalently adding adenosine monophosphate (AMP) to avoid its recognition by GAPs.45 Another effector protein, SidD, acts as deAMPylase.46,47 Type III secreted effectors can also display protease activities on Rabs, such as Salmonella‘s GtgE effector, which acts as a Rab32 protease.34

Concerning functionality, the salmonella effector protein, SopD, has been shown to enhance or inhibit inflammatory responses by targeting Rab8a signaling.40 The Legionella LidA-Rab6a interactions were shown to be required for bacterial intracellular replication and growth.48 Notably, these effector-rab structure-function relationships have been characterized for invading bacterial pathogens. As far as we know, no knowledge exists about such relations for extracellular bacterial pathogens, including the A/E pathogens. Here, we show for the first time that translocated EspH functionally interacts with multiple active Rabs, including Rab8a, Rab10, Rab3a, and Rab12. We also show that EspH possesses a putative phosphoinositide-binding domain (PBD), which plays a pivotal role in EspH localization at plasma membrane infection sites, likely by mediating effector binding to phosphoinositides (PIs). The PBD is also vital for maintaining the EspH-Rab interactions.

Materials and methods

Bacterial strains, antibodies, plasmids, primers

Bacterial strains, antibodies, plasmids, primers, and reagents used in this study are listed in the supplementary Table S1.

Cell culture and transfection of cells with plasmid DNA

HeLa and CaCo-2BBe cells (semi-polarized) (see Table S1) were cultured, as previously described.19 Plasmids were transiently transfected into HeLa cells (~60% confluence) for 48 hrs unless otherwise indicated using the TransIT-X2 Transfection Reagent protocol.

Construction of EspH mutants

The mutations were constructed on the pSA10-EspHwt-6×His-SBP encoding plasmid using PCR amplification of the vector and inserts and ligation using Gibson assembly. The vector was linearized using the 1F and 1 R oligonucleotides. The oligonucleotides 2F and 2 R or 3F and 3 R were used to mutate glutamic acid at position 37 to alanine or aspartic acid and generate the pSA10-EspHE37A and pSA10-EspHE37D (E37A/D; see Figure S1) encoding plasmids, respectively. Oligonucleotides 4F and 4 R or 5F and 5 R were used to mutate lysine at position 41 to alanine or arginine and generate the pSA10-EspHK41A or pSA10-EspHK41R (K41A/R; see Figure S1) encoding plasmids, respectively. Oligonucleotides 6F and 6 R were used to mutate lysine at position 106 to arginine and generate the pSA10-EspHK106R plasmid. Oligonucleotides 7F and 7 R were used to mutate tyrosine at position 68 to alanine (Y68A; see Figure S1) and create the pSA10-EspHY68A plasmid. Nucleotide sequences of all constructs were confirmed by the Genomic Technologies Facility (https://www.bio.huji.ac.il/en/units_the_national_center_for_genomic_technologies.) using SANGER sequencing. All the EspH mutant plasmids were electroporated at 1.85 kV/25 µF/200 Ohm, using the BioRad electroporator (GENE PULSER II) into the EPEC-ΔespH strains to generate the plasmid complemented bacterial strains.

Bacterial pre-activation and cell infection

Before infection, the T3SS of bacterial strains was activated in plain high glucose Dulbecco’s Modified Eagle Medium (DMEM) for 3 hrs in the CO2 incubator (37°C, 5% CO2, 95% humidity), as described.49 The expression of EspH in EPEC-ΔespH strains was induced by supplementing the activation medium with isopropyl-β-D-thiogalactopyranoside (IPTG; 0.05 mM for inducing EspHwt expression, 0.1 mM for inducing the EspH mutant expression, and as indicated in the Figures) during the last 30 min of activation. Cell infection was performed with the pre-activated infection medium in the CO2 incubator at 37°C for the indicated times. Bacterial infection was performed at a multiplicity of infection (MOI) of ~100.

SDS-PAGE and Immunoblotting

SDS-PAGE and immunoblotting (IB) were performed as described.50 Band intensity was measured using Fiji (NIH).

Effector translocation assay

The effector translocation assay was performed as described.49 Approximately 2 × 105 HeLa cells/well were seeded in a 6-well plate and cultured for 48 hrs until reaching ~70% confluence. Cells were then infected for 90 min at 37°C with the indicated EPEC strains, and IPTG was used to induce EspH expression. Following infection, cells were washed three times with ice-cold PBS and lysed in 60 µl of ice-cold lysis buffer [100 mM NaCl, 1 mM EDTA, 10 mM Tris-HCl, pH 7.4, 0.5% (vol/vol) NP-40] supplemented with protease and phosphatase inhibitors. Following 3 min incubation on ice, the lysate was pipetted up and down and then centrifuged (10,000 g, 4°C, 10 min). The supernatant (detergent-soluble) and pellet (detergent-insoluble) fractions were isolated. The pellet was resuspended in 60 µl of the lysis buffer. Twenty microliters of 4 × SDS-PAGE sample buffer were added to each lysis buffer containing fraction. The samples were then heated (95°C; 10 min) and analyzed by SDS-PAGE, followed by IB. The presence of EspH in the fractions was detected by anti-SBP antibodies. Anti-α-tubulin antibodies were used to assess the lysate protein load.

Analyzing EspH-Rab interactions by co-precipitation (pulldown) assays

HeLa or Caco-2BBe cells cultured on 15-cm plates (70% confluence) were infected for 90 minutes with pre-activated EPEC strains. Cells were washed three times with ice-cold PBS and lysed in ice-cold lysis buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 0.5% NP-40] supplemented with protease and phosphatase inhibitors. Lysates were centrifuged (5,000 g, 15 min, 4 °C), and the Bradford reagent was used to determine the supernatants’ protein concentration. EspH was precipitated (P) from an equal amount (~5 mg) of cell lysates by incubation with 60 µl of Streptavidin (StAv) agarose beads (50% slurry pre-washed with lysis buffer) for 3 hrs at 4°C with end-to-end rotation. Beads were washed three times with lysis buffer by centrifugation (300 g, 2 min, 4 °C), dried using Hamilton’s syringe, and subjected to SDS-PAGE followed by IB. Pulled-down EspH and co-precipitated Rabs were detected using anti-SBP and appropriate anti-Rab or epitope-tagged antibodies.

Fluorescence microscopy and colocalization analyses

Immunofluorescence labeling of permeabilized cells was performed as described.51,52

Cells were processed and imaged by an Olympus FV-1200 laser scanning confocal microscope equipped with a 60 × oil immersion objective (NA, 1.42), as described.52 Colocalization analyses using the intensity profile tool of Fiji (NIH) were performed, as described.52 Briefly, images for colocalization analyses were acquired under identical conditions. Colocalized labeling was scored when the fluorescence intensity co-peaked at a specific place along the line drawn to obtain a fluorescence intensity profile. Data are presented as percentages of colocalizing fluorescence intensities of the profiles. Notably, the anti-SBP antibodies recognized specifically the translocated EspH (see Figure S2). Infection with EPEC-ΔespH (not expressing EspH), or EPEC-escV/pEspHwt (not translocating EspH) yielded low near background fluorescence levels compared to the high fluorescence intensity levels observed in cells infected with EPEC-ΔespH/pEspHwt (translocating EspH) (Figure S2). Scale bars = 5 μm.

The β-hexosaminidase activity (release) assay

Lysosomal exocytosis was evaluated using the β-hexosaminidase activity measurements in HeLa-infected cells, as described.50

Bacterial invasion and filopodia formation measurements

Bacterial invasion and the induction of transient filopodia in infected HeLa cells were measured, as described.17

Akt/mTORC1 activity measurements

HeLa or Caco-2BBe cells cultured on 10-cm plates (70% confluence) were infected for 90 min with pre-activated EPEC. Cells were then washed three times with ice-cold PBS and lysed in ice-cold lysis buffer [50 mM Tris (pH 7.6), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 2 mM MgCl2, 100 mM NaF, 200 μM NaVO4, 1 mM PMSF, 1 µM leupeptin and 1 µM aprotinin]. Lysates were centrifuged (10,000 g, 10 min, 4 °C), and the protein concentration of the supernatants was determined using the Bradford reagent. An equal amount of protein (~100 µg) was analyzed by SDS-PAGE, followed by IB. Active Akt and mTORC1 levels were evaluated by probing the blots with antibodies directed to phosphor (p) Akt (Ser473) or phosphor (p) 4E-BP1, respectively. The band intensities of phosphorylated proteins were first normalized to total (t) Akt or 4E-BP1 protein band intensities, then to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein band.

Establishing a HeLa Rab8a knock-out (KO) cell line by a lentivirus-based CRISPR/Cas9 genome editing system

Lentivirus preparation

The gRNA sequences (8F’ and 8 R’; see Table S1) targeting the human Rab8a gene were cloned into lentiCRISPR V2 lentiviral vector (Table S1) as described by the Zhang laboratory (https://media.addgene.org/data/plasmids/52/52961/52961-attachment_B3xTwla0bkYD.pdf). To produce the lentiviruses, HEK293T/SF17 cells were seeded (3.8 × 106 cells/plate) onto 10-cm plate and grown for 24 hrs in a CO2 incubator. Then, the cells were treated with 10 µl of 25 µM chloroquine and incubated in a CO2 at 37°C incubator for 5 hrs. Thereafter, the cells were transfected with a mixture of psPAX2 (10 µg), pMD2.G (6 µg), and either gRNA-containing lentiCRISPRV2 (10 µg) or empty lentiCRISPRV2 (10 µg) plasmids, using polyehyleneimine (PEI; DNA: PEI 1:3 w/w ratio), and incubated in the CO2 incubator for 16 hrs. Then, the transfection medium was replaced after 6 hrs with a complete DMEM lacking antibiotics to allow viral particle production and release for 48 or 96 hrs. The virus-containing medium was harvested, pooled, and centrifuged (500 × g, 10 min, 22 °C), and the supernatant was clarified by passing through a 0.45 μm filter unit. Viral particles were concentrated by gently mixing one volume of PEG8000 solution 32% w/v in PBS with 3 volumes of clarified supernatant and incubated for 30 min at 4°C, followed by centrifugation (1,500 × g 45 min 4°C). The viral pellet was dissolved in 12 ml of complete DMEM without antibiotics.

Cell infection and clone isolation

HeLa cells were seeded in a 6-well plate (1.5 × 105 cells/well) and incubated for 24 hrs in the CO2 incubator before infection. The cells were then infected with 2 ml of the concentrated lentiviral preparation supplemented with 8 ug/ml polybrene and incubated for 24 hrs in the CO2 incubator. The cell infection treatment was repeated for three successive days. After the third infection, cells were washed with PBS and selected with complete DMEM containing puromycin (3 µg/ml) for 48 hrs. Cells were then cultured in 10-cm plates at 50 cells/plate in DMEM containing puromycin (3 µg/ml) and allowed to grow in the CO2 incubator for approximately ten days until single cell colonies were identified. Individual cell colonies were then picked by trypsinization and expanded for analysis of Rab8a expression by IB (Figure S3).

Lactate dehydrogenase (LDH) cytotoxicity assay

HeLa cells (10,000 cells/well) were seeded on a 96-well plate and cultured for 48 hrs in a CO2 incubator until reaching ~70% confluence. Cells were infected with EPEC, and the LDH release assay was applied to the cell culture medium using the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega). The cytotoxicity was calculated as follows: Cytotoxicity% = Experimental LDH Release (OD490)/Maximum LDH Release (OD490) [Percentage cytotoxicity=100×Experimental LDH Release  (OD490 Maximum LDH Release  (OD490], whereby ‘Experimental LDH Release’ denotes the LDH release into the medium bathing the cells; ‘Maximum LDH Release’ represents the LDH levels in cells lysed with 1X lysis solution provided by the kit.

Statistical analysis

The GraphPad Prism v. 8.4.3 software was used for statistical analysis and graphing. A one-way ANOVA followed by Bonferroni’s multiple-comparison test was applied to determine the statistical significance. The significance is indicated by asterisks, as follows: ****p ≤ 0.0005; ***p > 0.0005; **p < 0.005; *p > 0.005; ns, non-significant p > 0.05. A p-value <0.05 indicates a statistically significant difference.

Results

Translocated EspH interacts with the human Rab GTPases Rab8a, 10, 3a, and 12

Using co-precipitation followed by mass spectrometry and proteomics analysis, we have previously shown that EspH co-precipitated with multiple Rab GTPases, including Rab8a, Rab10, Rab3 (a and d), and Rab12, Rab1 (a and b) and Rab39a.17 It has been suggested that these Rabs interact with a region in EspH located upstream of the C-terminal 38-amino acid (aa) segment.17 The current study focused mainly on Rab8a (Figure 1a,c), Rab10 (Figure 1b,d), Rab3a [eGFP-Rab3awt (Figure 1e)], and, to some extent on Rab12 [Flag-Rab12wt (Figure 1f)]. To confirm these findings by IB, HeLa (Figure 1a,b,e,f) or Caco-2BBe (Figure 1c,d) cells were infected with an espH deleted EPEC strain (EPEC-ΔespH), used as a negative control, or with an EPEC-ΔespH complemented with a plasmid expressing wild-type (wt) EspH with six histidines (6 × His) and a streptavidin binding peptide (SBP) tags located at the C-terminus of the effector protein (EPEC-ΔespH/pEspHwt). Cells were lysed, and EspH was precipitated using Streptavidin (StAv) agarose beads. SDS-PAGE, followed by IB, was used to analyze precipitated EspH and co-precipitated Rabs. The results showed that the Rabs co-precipitated with EspH from the EPEC-ΔespH/pEspHwt infected cells (Figure 1). Notably, the co-precipitated eGFP-Rab3awt (Figure 1e), Rab10 (Figure 1b,d) and Flag-Rab12wt (Figure 1f) appeared as two protein bands, possibly as the result of Rab undergoing post-translational modifications.53 Figure 1. Rab8a, Rab10, Rab3a and Rab12 co-precipitate with translocated EspHwt.

HeLa cells were infected with the indicated EPEC strains, lysed, and subjected to co-precipitation analyses, as described in Materials and Methods. SBP-tagged EspHwt was precipitated (P) by streptavidin (StAv) beads, and anti-SBP antibodies were used to identify the precipitated EspH by IB. The co-precipitated endogenous Rab proteins were detected by IB, using antibodies directed against them (panels a-d) or anti-eGFP or anti-Flag tag antibodies in cases where epitope-tagged Rabs were ectopically expressed (e and f). The same antibodies were used to identify the Rabs in cell lysates. Anti-β-actin (αβ-actin) or anti-α-tubulin (αα-tubulin) antibodies were used for detecting protein loading. The endogenous Rab8a and Rab10 co-precipitation was examined in HeLa (a–b) and Caco-2BBe (c–d) cells. The co-precipitation of the ectopically expresed eGFP-Rab3a and Flag-Rab12 with EspH was examined in HeLa cells (e-f). Representative gels from at least three independent experiments are shown.

Additionally, the endogenous Rab8a co-precipitated with EspH from EPEC-ΔespH/pEspHwt and from cells infected with EPEC-ΔespH complemented with a plasmid expressing EspH whose C-terminal 38 aa ABR binding domain (Figure S1) was deleted (EPEC-ΔespH/pEspH∆130-168) (Figure S4). These results are consistent with our proteomics analyses,17 suggesting that the Rabs interact with the translocated EspH via a region located upstream to the C-terminal 38 aa segment.

EspH interacts with the active Rab forms

Using the same co-precipitation approach, we examined the capacity of translocated EspHwt to co-precipitate the ectopically expressed GFP-Rab8awt, eGFP-Rab3awt and eGFP-Rab10wt, the dominant negative (GDP-locked) GFP-Rab8aT22N, eGFP-Rab3aT36N and eGFP-Rab10T23N and the constitutively active (GTP-locked) GFP-Rab8aQ67L, eGFP-Rab3aQ81L and eGFP-Rab10Q58L. The wt, the constitutively active but not the dominant negative Rabs, co-precipitated with EspHwt from EPEC-ΔespH/pEspHwt infected cells (Figure 2a and Figures. S5a and c). Confocal imaging confirmed these results, showing that translocated EspHwt colocalized with the wt and the constitutively active but not with the dominant negative Rabs (Figure 2b and Figures S5b and d). These results suggest that EspH selectively binds active Rabs. Figure 2. Translocated EspHwt interacts with active Rab8a. Analysis by co-precipitation.

(a). HeLa cells ectopically expressing the wild-type (wt), T22N (GDP-locked), and Q67L (GTP-locked) GFP-tagged Rab8a were infected with EPEC-ΔespH or EPEC-ΔespH/pEspHwt for 90 min at 37°C and subjected to co-precipitation experiments, as in Figure 1. A representative gel from three independent experiments is shown. Colocalization analysis (b). HeLa cells expressing the eGFP-tagged Rabs were infected with EPEC-ΔespH/pEspHwt, fixed, permeabilized, and immunostained with anti-SBP antibodies to visualize EspH. Cells were also stained with DAPI (to visualize cell nuclei and bacterial microcolonies) and Phalloidin CF-647 (F-actin), and imaged by confocal microscopy. Representative images from three independent experiments are shown. The green (Rab) and the red (EspH) channels were merged. Arrows point toward infecting EPEC microcolonies. An enlargement of the boxed region in the merged image is shown, along with a line used to generate fluorescence intensity profiles of EspH and Rab. Arrows in the fluorescence intensity profiles point toward co-peaking fluorescence intensity signals. The bar graph depicts the percentage of colocalization between the Rabs and EspH derived from 10 intensity profiles. Results are mean ± SE. The results of parallel experiments involving eGFP-Rab3a and eGFP-Rab10 are shown in Figure S5a and b and Figure S5c and d, respectively.

AlphaFold calculated structures show a shared binding interface between EspH and the Rabs, where EspH residues E37 and K41 are implicated in Rab-binding

AlphaFold-Multimer-v2.0 was used to calculate complexes of EspH (pink) and the different Rabs (gray) (Figure 3a–e). The predicted alignment error (PAE) showed high confidence in the binding regions of Rab3a and Rab10, with a somewhat reduced confidence in binding Rab8a and a significantly reduced confidence in binding Rab12 (Figure 3f), suggesting that the interactions of EspH with these Rabs are weak. In all calculated structures, residues E37 and K41 located in an α-helix of EspH interacted with corresponding Lys (K) and Asp (D) residues located in a β-strand of the interswitch region of the Rabs. Specifically, E37 and K41 of EspH with D45 and K47 residues of Rab10 (Figure 3b), D44 and K46 in Rab8a (Figure 3c), D58 and K60 in Rab3a (Figure 3d), and D78 and K80 in Rab12 (Figure 3e). F10 in EspH seems to interact with Rab10 or Rab3a (Figure 3b,d) via F46 and W63 in Rab10 and F59 and W76 in Rab3a. Interestingly, the aromatic F and W residues in the Rabs are among the three amino acids that make up the hydrophobic triad defined as F45, W62, and Y77 of human Rab8a, which interacts with the Legionella LidA effector.38 These additional interactions correlate with the increased confidence of binding of Rab10 and Rab3a with EspH, shown in the PAE plots (Figure 3f). Notably, the predicted Rab binding residues of EspH from different E. coli species are highly conserved, and as expected, are located upstream to the ABR binding C-terminal 38 aa domain (Figure S1). Figure 3. AlphaFold predicted structures for binding interfaces of EspH-Rabs.

The complexes of EspH-Rab10 (a-b), EspH-Rab8a (c), EspH-Rab3a (d), and EspH-Rab12 (e) were modeled using AlphaFold-Multimer-v2.0. The EspH (pink) and the Rab GTPase (gray) structures are depicted. The switch I, interswitch, and switch II Rab domains are shown in maroon, dark green, and navy blue, respectively. (a-b). The EspH-Rab10 binding interface. The Rab10-EspH complex is shown in panel a, and the interface area (dashed boxed) is enlarged in panel b, where the predicted interacting E37 and K41 of EspH (yellow) and K47 and D45 of Rab10 interswitch region (green) are shown. F10 (pink) of EspH interacts with F46 (bright green) and W63 (bright green) of Rab10. The non-interacting K106 of EspH (orange) is also indicated (panel a). (c). The EspH and Rab8a binding interface. (d). The EspH-Rab3a binding interface. (e). The EspH-Rab12 binding interface. The interacting E37 and K41 residues of EspH (yellow) respectively interact with K46 and D44 in Rab8A (c), with K60 and D58 in Rab3a (d), and with K80 and D78 in Rab12 (e), all located in the interswitch region (green). F10 of EspH (pink) interacts with F59 and W76 in Rab3a (d). (f). Predicted Aligned Error (PAE) plots for EspH and the denoted Rab proteins. The PAE matrices were calculated for each EspH-Rab complex using the AlphaFold program. In these matrices, both axes show the position of the indicated residues of both proteins, starting with EspH, consecutively numbered. The score presents the calculated error of the predicted distance for each pair of residues color-coded from blue (0 angstroms) to red (30 angstroms), as shown in the right bar, where a low predicted error, blue, indicates higher certainty regarding the relative position of the two amino acids. The diagonal blue shows amino acids that are sequential in the primary sequence and are also adjacent in space. Blue coding between EspH and the Rabs in the off-horizontal region indicates high certainty in the regions of intermolecular interaction.

Residues E37 and K41 of EspH are crucial for Rab binding

We performed site-directed mutagenesis to explore the significance of E37 and K41 of EspH in Rab binding, whereby the indicated residues were individually mutated to alanine (A) (Figure S1). EPEC-ΔespH mutant strains complemented with plasmids encoding the EspH mutant EspHE37A (EPEC-ΔespH/pEspHE37A) or EspHK41A (EPEC-ΔespH/pEspHK41A) were generated, and their ability to express and translocate EspH was confirmed (Figure S6a and b). HeLa cells were infected with these bacterial strains and subjected to the Rab co-precipitation approach. The results show that EspHE37A and EspHK41A failed to co-precipitate endogenous Rab8a (Figure 4a), eGFP-Rab3awt (Figure 4b), and the endogenous Rab10 (Figure 4c). Similar results were obtained with the endogenous Rab8a in Caco-2BBe infected cells (Figure S7). Figure 4. The predicted Rab binding residues in EspH are critical for EspH-Rab interactions and are highly susceptible to mutagenesis.

HeLa cells were infected for 90 min at 37°C with the indicated EPEC strains. The capacity of the endogenous Rab8a (a and d), eGFP-Rab3awt (b), and endogenous Rab10 (c) to co-precipitate with EspH was examined as described in Materials and Methods, and Figure 1. Representative gels from three independent experiments are shown.

Next, we explored whether conservative mutations of E37 and K41 also affected Rab binding. For this purpose, EPEC-ΔespH complemented with EspHE37D, or EspHK41R encoding plasmids were generated (Figure S1). The mutant effector translocation into HeLa cells was confirmed (Figure S6d and e). Interestingly, these EspH mutants also failed to co-precipitate the endogenous Rab8a (Figure 4d). Conversely, mutating a remotely located K106 to arginine (K106R; see Figure S1), whose expression and translocation into the host cells have been confirmed (Figure S6c), did not detectably impact EspH’s ability to co-precipitate the Rabs (Figure 4a–c). Consistent with the co-precipitation data, colocalization analysis of translocated EspHK106R, EspHE37A, and EspHK41A with GFP-Rab8a, eGFP-Rab10, or eGFP-Rab3a, expressed in HeLa cells showed that while EspHK106R colocalized significantly with the Rabs, the other two mutants did not (Figure S8a–d). These results support the understanding that residues E37 and K41 of EspH are critical for mediating the EspH-Rab interactions.

EspH-Rab interactions are functionally relevant

Next, we investigated the impact of EspH-Rab interactions on the infected cells, focusing on previously suggested roles for these Rabs. For example, Rab8a and Rab10 have been implicated in regulating class I phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin complex 1 and 2 (mTORC1/C2) signaling.54–62 Therefore, EspH-Rab8a interactions may affect the PI3K/Akt/mTOR signaling pathways. To address this hypothesis, we have initially tested whether translocated EspHwt affects the levels of active Akt and mTORC1 by IB using antibodies directed against phosphorylated Ser473 of active Akt [α-pAkt (Ser473)], or against phosphorylated Thr37/46 of active 4EBP1 [α-p4EBP1 (Thr37/46)]. In these experiments, HeLa cells were infected, or not (uninfected), with EPEC-escV, EPECwt, EPEC-ΔespH, EPEC-ΔespH/pEspHwt. Cells were lysed, and cell lysates were subjected to SDS-PAGE followed by IB analyses using the indicated antibodies. Cell infection with EPEC-escV increased pAkt levels compared to uninfected cells (Figure S9), a phenomenon that the bacterial lipopolysaccharide could contribute.60 Infection with EPECwt diminished the pAkt and p4EBP1 levels compared to EPEC-escV infected cells. Interestingly, infection with EPEC-ΔespH unaffected those levels, whereas infection with EPEC-ΔespH/pEspHwt caused a significant reduction in both pAkt and p4EBP1 (Figure S9). These data argue that translocated EspHwt inhibits the PI3K/Akt/mTORC1 signaling.

To explore the role of EspH-Rab interactions, HeLa cells were infected with EPEC-ΔespH, EPEC-ΔespH/pEspHwt, EPEC-ΔespH/pEespHK106R, EPEC-ΔespH/pEspHE37A and EPEC-ΔespH/pEspHK41A and the Akt and mTORC1 activity level was evaluated as described above. Cell infection with EPEC-ΔespH/pEspHwt or EPEC-ΔespH/pEspHK106R resulted in a significant diminishment of pAkt(Ser473) and p4EBP1 (Thr37/46) levels compared to EPEC-ΔespH infected cells (Figure 5a). In contrast, the levels of pAkt (Ser473) and p4EBP1 (Thr37/46) in cells infected with EPEC-ΔespH/pEspHE37A, or EPEC-ΔespH/pEspHK41A were comparable to those detected in EPEC-ΔespH infected cells (Figure 5a). Similar results were obtained in Caco-2BBe infected cells (Figure S10). These results indicate that EspH inhibits the pI3K/Akt/mTORC1 signaling pathway, possibly through inhibiting Rab8a and Rab10. Figure 5. The Rab binding residues in EspH are critical for exerting Rab-related functions.

HeLa cells were infected with the indicated EPEC strains for 90 min at 37°C, and the effects on Akt and mTORC1 signaling (a), lysosome exocytosis (b), and bacterial invasion (c) were measured, as described in Materials and Methods. All experiments were repeated at least three times. Representative gels (panel a, left) from three independent experiments and their quantification (panel a, right) are shown. Results are mean ±SE.

Rab3a and Rab10 have been implicated in regulating lysosomal exocytosis.63–65 We have recently shown that EPEC infection stimulates lysosomal exocytosis in a T3SS-dependent manner, involving the death-promoting effectors Tir, EspF, and Map.50 The observation that EspH interacts with Rab3a and Rab10 (Figures 1,3,4, S5a–d) prompted the hypothesis that the effector modulates lysosomal exocytosis. To test this, cells were infected with EPEC-wt, or EPEC-escV, or EPEC-ΔespH/pEspHwt, or EPEC-ΔespH/pEspHK106R, or EPEC-ΔespH/pEspHE37A, or EPEC-ΔespH/pEspHK41A. The β-hexosaminidase activity (release) assay was applied to measure lysosomal exocytosis.50 Infection with EPEC-escV showed reduced lysosomal exocytosis compared to EPEC-wt-infected cells, confirming the involvement of the T3SS in the process (Figure 5b). EPEC-ΔespH infection resulted in slightly higher lysosomal exocytosis levels than in EPEC-wt infected cells (Figure 5b). Infection with EPEC-ΔespH/pEspHwt or EPEC-ΔespH/pEspHK106R caused a significant reduction in these levels (Figure 5b), suggesting that injected EspH inhibits lysosomal exocytosis. In contrast, infection with EPEC strains expressing the Rab-interaction deficient mutants (EspHE37A and EspHK41A) showed higher lysosomal exocytosis levels (Figure 5b). These data suggest that translocated EspH inhibits lysosomal exocytosis, possibly through binding and modulating the activity of Rab3a or Rab10.

Studies on Salmonella showed that inhibiting Rab10 by the SopD effector promoted Dynamin-2 recruitment and plasma membrane scission during bacterial invasion.37 Studies have also shown that EspH inhibits EPEC invasion by inhibiting CDC42 and Rac1 GTPases.16,17 However, these observations do not exclude the existence of other mechanisms, such as the interactions of EspH with host Rabs. Infection with EPEC-ΔespH/pEspHwt, or EPEC-ΔespH/pEspHK106R displayed significantly reduced invasion levels compared to EPEC-ΔespH. In contrast, infection with EPEC-ΔespH/pEspHE37A or EPEC-ΔespH/pEspHK41A showed higher invasion levels, comparable to those displayed by EPEC-ΔespH infected cells (Figure 5c). These data support the hypothesis that EspH inhibits bacterial invasion by binding and modulating the activity of Rabs, possibly Rab10.

Effects of EspH on Rab8a deficient cells

Given the vital role of Rab8a in PI3K/Akt/mTORC1 signaling as a mechanism that limits innate immune responses,60,62 we studied whether the EspH-mediated inhibition of these signaling pathways (Figure 5a) depends on Rab8a. For this purpose, a lentiviral vector-based CRISPR/Cas9 genome editing system was used to generate HeLa cell lines deficient in Rab8a expression [Rab8a-knock-out (KO) cells, Figure S3]. HeLa cells transduced with empty lentiviral vector and, therefore, not hampered Rab8a expression were used as controls in these experiments (Control-KO cells). To test the effects of translocated EspH, data obtained in EPEC-ΔespH/pEspHwt infected cells were compared to those of EPEC-ΔespH infected cells. While a significant reduction in the pAkt and p4EBP1 levels was observed in the Control-KO cells infected with EPEC-ΔespH/pEspHwt, a minor insignificant reduction was seen in the Rab8a-KO1 cells (Figure 6a). These results agree with the view that EspH-Rab8a interactions play a role in the inhibition of PI3K/Akt/mTORC1 signaling. In addition, our results show that the inhibition of lysosomal exocytosis is significantly reduced in the Control-KO but not in the Rab8a-KO1 EPEC-ΔespH/pEspHwt infected cells (Figure 6b), suggesting that EspH-Rab8a interactions could play a vital role in lysosomal exocytosis inhibition. However, the inhibition of bacterial invasion by translocated EspH was reduced to similar levels in the Control-KO and Rab8a-KO1 cells (Figure 6c), indicating that EspH-Rab8a interactions are not involved in bacterial invasion. Co-precipitation followed by IB analysis showed that eGFP-Rab3a and eGFP-Rab10 co-precipitated with translocated EspH from the Rab8a and Control-KO cells, albeit with different efficacies. The Rab3a and Rab10 co-precipitated at lower levels in the Rab8a KO1 cells compared to the Control-KO cells (Figure 6d). These results suggest that the interactions between EspH and Rab8a could play a role in maintaining optimal interactions with other Rabs. Figure 6. Interactions of EspH with Rab8a are essential for eliciting the AkT/mTORC1 signaling, lysosomal exocytosis, and the interactions with Rab3a.

Control-KO and Rab8a-KO1 HeLa cells (Figure S3) were infected with the indicated EPEC strains for 90 min at 37°C, and the effects on Akt and mTORC1 signaling (a), lysosome exocytosis (b) and bacterial invasion (c), were measured, as described in Materials and Methods and Figure 5. (d) Interactions of translocated EspH with Rab3a and Rab10. Control-KO and Rab8a-KO1 HeLa cells were transfected with eGFP-Rab3a and eGFP-Rab10 encoding plasmids for 48 hrs and then infected for 90 min with the indicated EPEC strains. Co-precipitation experiments were performed, as in Figure 1. Precipitated EspH and co-precipitated Rabs were detected with anti-SBP and anti-GFP antibodies, respectively. Rab levels in cell lysates were detected with anti-GFP antibodies. Anti-GAPDH antibodies were used to assess the protein load. The level of the co-precipitated (‘pulldown’) Rabs was calculated by measuring the intensity of the co-precipitated protein band normalized to the intensity of the protein band detected in the cell lysate and the intensity of the GAPDH band. The values obtained were further normalized to the Control-KO levels. All experiments were repeated at least three times. Representative gels from at least three independent experiments are shown. Results are mean ±SE.

EspH-Rab interactions do not play a role in stimulating host cytotoxicity and filopodia repression

Studies have shown that translocated EspH induces host cell cytotoxicity and inhibits transient filopodia formation, functions attributed to Rho GTPase inhibition.17 Infection of HeLa cells with EPEC-ΔespH/pEspHE37A or EPEC-ΔespH/pEspHK41A did not affect host cell cytotoxicity (Figure 7a) or filopodia repression (Figure 7b) compared to EspHwt infected cells, suggesting that Rab binding by EspH is not involved in these processes. These results further signify the existence of two distinct functional motifs in EspH: one is the C-terminal 38aa segment that binds ABR to downregulate Rho GTPases, inducing cell cytotoxicity and repressing filopodia formation,17 and the other is the Rab binding motif located upstream of this segment, involved in modulating Rab GTPases and their role in Akt/mTORC1 signaling, lysosomal exocytosis and bacterial invasion. Figure 7. The effects of mutations in EspH used to study the interactions with Rab GTPases on host cell cytotoxicity and filopodia formation.

HeLa cells were infected for 90 or 15 min with the indicated EPEC strains, and the impact on cell cytotoxicity using the LDH release assay (a) or filopodia formation by confocal cell imaging (b), respectively, was measured as described in Materials and Methods. For cell imaging, EspH was immunostained by anti-SBP antibodies, host cell nuclei and bacterial microcolonies were visualized by DAPI staining, and F-actin was observed by Phalloidin Texas Red staining. Representative images from three independent experiments are shown. Results are mean ± SE. Statistical significance tests were performed versus the EPEC-∆espH/EspHwt infected cells.

A PBD of EspH mediates effector localization at plasma membrane infection sites and interactions with Rab8a

A common conserved GKxYxnF PBD with a critical tyrosine has been identified in type III-secreted effectors, mediating high-affinity interactions with PI-enriched membrane platforms.66 Interestingly, we identified the conserved domain in EspH expressed by several pathogenic E. coli species, including EPEC, and thus mutated its conserved tyrosine at position 68 to alanine (Y68A; Figure S1). The expression and translocation of EspHY68A into HeLa cells infected with EPEC-ΔespH/pEspHY68A was confirmed (Figure S6f). HeLa cells expressing eGFP-PH-Akt [a reporter of PI(3,4)P2 and PI(3,4,5)P3] or eGFP-PH-TAPP1 [a reporter of PI(3,4)P2]67 were infected with EPEC-ΔespH/pEspHwt or EPEC-ΔespH/pEspHY68A. Confocal imaging showed that translocated EspH colocalized extensively with each PI reporter in large patches at the plasma membrane infection sites. The translocated EspHY68A neither clustered nor colocalized with the PI sensors at the infection sites (Figure 8a). These results may agree with previous reports, suggesting the existence of PI-enriched membrane platforms at infection sites68–70 with which EspH interacts via its PBD. These interactions may promote EspH preferential localization and PI clustering at these sites. Figure 8. The EspH PBD is critical for EspH localization at infection sites, PI clustering, and interactions with Rab8a.

(a). PI clustering at infection sites. HeLa cells were transfected with eGFP-PH-Akt (upper) or eGFP-PH-TAPP1 encoding plasmids (lower). Eighteen hours post-transfection, cells were infected with EPEC-ΔespH/pEspHwt or EPEC-ΔespH/pEspHY68A strains for 30 min at 37°C. Cells were fixed, permeabilized, and immunostained with anti-SBP antibodies to visualize EspH (red). Cells were then stained with DAPI (blue) to visualize host nuclei and adhered bacterial microcolonies (indicated with arrowheads) and analyzed by confocal microscopy. The colocalization analysis was performed as described in Figure 2b. The bar graph depicts the percentage of colocalization derived from 3 intensity profiles. (b) Interactions with Rab8a;Analysis by co-precipitation (left). HeLa cells were infected for 90 min with the indicated EPEC strains, and co-precipitation experiments detecting the endogenous Rab8a were performed, as in Figure 1. Analysis by colocalization (right). HeLa cells were transfected with a GFP-Rab8awt encoding plasmid and infected with the indicated EspH-expressing EPEC strains. Colocalization analyses were performed, as described in Materials and Methods and Figure 2b. (c) Effects on Akt/mTORC1 activities. HeLa cells were infected for 90 min with the indicated EPEC strains, and the activity assay was performed as described in Materials and Methods and Figure 5. (d) Effects on bacterial invasion. HeLa cells were infected for 90 min at 37°C with the indicated EPEC strains, and the invasion assay was performed as described in Materials and Methods and Figure 5c. (e) Effects on host cytotoxicity. HeLa cells were infected with the indicated strains for 90 min at 37°C, and the LDH release assay was used to evaluate the impact on cell cytotoxicity. All experiments were repeated at least three times. Representative gels are shown. Results are mean ±SE.

Next, we examined whether the PBD is essential for the EspH-Rab8a interactions. HeLa cells infected with EPEC-ΔespH (a negative control) EPEC-ΔespH/pEspHwt or EPEC-ΔespH/pEspHY68A, were subjected to the Rab co-precipitation method. The endogenous Rab8a co-precipitated with EspHwt but not EspHY68A (Figure 8b, left). Confocal imaging showed significant colocalization between GFP-Rab8a and translocated EspHwt, but not EspHY68A, in large clusters at infection sites (Figure 8b, right). Notably, the Alphafold predicted structure of EspH-Rab8a suggested that Y68 of the EspH PBD is distinct from the Rab binding interface (Figure S11). While infection with EPEC-ΔespH/pEspHwt showed a significant reduction of pAkt and p4EBP1 levels compared to EPEC-ΔespH, cells infected with EPEC-ΔespH/pEspHY68A displayed an impaired ability to dephosphorylate Akt and 4EBP1 (Figure 8c). While infection with EPEC-ΔespH/pEspHwt caused significant inhibition of bacterial invasion compared to EPEC-ΔespH infected cells, infection with EPEC-ΔespH/pEspHY68A did not yield an effect (Figure 8d). Unlike translocated EspHwt which, as previously demonstrated,15,17 induced cytotoxicity, translocated EspHY68A had no impact on host cytotoxicity (Figure 8e). These data argue that the PBD of EspH is significant for its interactions with host Rab8a. They also indicate that the interactions are important for exerting EspH-dependent suppression of Akt, mTORC1, bacterial invasion into the host cells, and induction of host cytotoxicity. Thus, the interactions of EspH with plasma membrane PIs are vital for exerting all its reported functions.

Discussion

EspH, an effector protein known for its ability to disrupt the host cell actin cytoskeleton by inhibiting Rho GTPases,14–19,71 is shown here to interact with several Rab GTPases, including Rab8a, Rab10, Rab3a, and Rab12 (Figures 1–4). In this regard, EspH joins a list of bacterial effector proteins shown to bind multiple host Rabs.33–40 The ability of EspH to bind these Rabs at different time points of infection and precipitate them from cell lysates (Figure S12) suggests that the binding is firm and occurs even at an early infection phase, an idea consistent with reports for other effector-Rab interactions.32,38 The mechanism by which EspH affects the host Rabs remains unknown. However, it would be conceivable to assume that it inhibits normal signaling pathways by binding the active Rab forms (Figure 2 and Figure S5). It would also be reasonable to hypothesize that EspH-mediated inhibition of Akt/mTORC1 signaling by binding active Rab8a (Figure 6a) causes the inhibition of downstream cytokine secretion and inflammatory responses, as described earlier in the case of lipopolysaccharide-treated macrophages60,62 and for the Salmonella SopD effector protein.40

We have recently shown that lysosomal exocytosis is linked to the translocation of death-promoting effectors, e.g., Tir, EspF, and Map.50 Here, we show that translocated EspH inhibited lysosomal exocytosis in a Rab8a-dependent fashion (Figure 6b). mTORC1 signaling has been tightly linked to lysosomal positioning and trafficking.72–74 Hence, the downregulation of mTORC1 activity by EspH-Rab8a interactions (Figure 6a) may play a role in lysosomal exocytosis inhibition (Figure 6b). The efficiency of Rab3a to co-precipitate with EspH is reduced in the absence of Rab8a (Figure 6d), suggesting that the capacity of the effector to interact with Rab3a depends on Rab8a binding. As Rab3a has also been proposed to modulate lysosomal exocytosis,63,64 the reduced capacity of EspH to inhibit lysosomal exocytosis in the Rab8a-deficient cells may be contributed by reduced Rab3a binding. EspH induces cell cytotoxicity, imposing cell rounding and plasma membrane damage.17 Lysosomal exocytosis regulated by Rab10 and Rab3a has been implicated in membrane repair.64 The potential blockade of host membrane repair by EspH may represent a novel type of cell stress imposed by the effector.

AlphaFold identified residues in an α-helix of EspH (E37 and K41) that bind the K and D residues in the β-strand interswitch region of all the indicated Rabs, suggesting this is a common characteristic in Rab binding (Figure 3). Crystallographic studies have found similar effector-Rab interactions: e.g., α-helices in Legionella LidA that bind the two switches and the interswitch of Rab1 via polar aa and salt bridges.39 The structure of the complex (PDBid 3SFV) shows interactions between K49 and D47 on a β-strand of Rab1 to the corresponding D235 and K239 on LidA, similar to the E37 to K and K41 to D of EspH-Rab interactions. Similarly, the Salmonella SopD effector displays a large interaction interface with Rab8a, including experimentally identified E293 and K285 in an α-helix in the effector protein that interacts with K58 and Q60, respectively, in the interswitch β-strand of Rab8a.40

A hydrophobic interaction was seen between the hydrophobic triad (F45, Y77, and W62) in human Rab8a and LidA.38 We also found aromatic interactions between F46 and W63 of the hydrophobic triad of Rab10 and F59 and W76 of Rab3a, with F10 of EspH (Figure 3b,d). These interactions may contribute to stronger binding, which may be why the PAE confidence is higher for these complexes in the AlphaFold structures (Figure 3f). In conclusion, the Rab-effector structural interface, exemplified in the case of EspH-Rab binding and found in other bacterial effector-Rab interfaces, may reflect a common mode of binding that enables the functional manipulation of multiple Rabs by these effectors and contributes to pathogenesis.

Our data indicate that plasma membrane PIs play a role in enabling the EspH-Rab interactions (Figure 8). PI sensors and translocated EspHwt clustered significantly at the infection sites. The clustering effect was markedly reduced in the presence of EspHY68A (Figure 8a). Interestingly, Tir has been suggested to buildup of PI(3,4)P2 and PI(3,4,5)P3 enriched platforms at plasma membrane infection sites.68–70 EspH may further augment this effect by binding and clustering host PIs via its PBD. Plasma membrane PI domains have been implicated in the recruitment and regulation of Rab and Rho GTPases spatiotemporal signaling.75–77 Therefore, the EspH-PI interactions at bacterial infection sites may represent another mechanism by which the effector protein impacts the structure and function of host Rab and Rho GTPases.

As an extracellular bacterial pathogen, EPEC elicits mechanisms that block its invasion (phagocytosis) into the host cells, enabling it to remain extracellular.78 These mechanisms involve the inhibition of Rho GTPases by EspH,16,17 EspG-mediated counteracting of the WAVE regulatory complex,79 and inhibition of PI3K-dependent signaling pathways.80 Here, we propose another anti-phagocytic mechanism involving EspH binding to host Rabs (Figure 5c), possibly by binding Rab10.37 This hypothesis will be further addressed by knocking out or down the expression of Rab10 in the host cells.

In summary, our studies suggest that the effector protein EspH of A/E pathogens contains PI, ABR, and Rab GTPase binding domains. EspH utilizes a PBD to confine its localization at plasma membrane infection sites. These interactions facilitate the binding and downregulation of the activity of host Rho (through binding ABR) and Rab GTPases to disrupt the actin cytoskeleton, lysosomal trafficking, and immune signaling pathways, thereby contributing to bacterial pathogenesis.11

Supplementary Material

Supplemental Material

Acknowledgment

Ipsita Nandi, Rachana Pattani Ramachandran, Deborah E. Shalev, Dina Schneidman-Duhovny, Raisa Shtuhin-Rahav, Naomi Melamed-Book, Ilan Rosenshine, Benjamin Aroeti (2024). EspH utilizes phosphoinositide and Rab binding domains to interact with plasma membrane infection sites and Rab GTPases. bioRxiv, 2024-06. Link: https://www.biorxiv.org/content/10.1101/2024.06.28.601186v1.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from the corresponding author, BA, upon reasonable request.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/19490976.2024.2400575
==== Refs
References

1. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev. 1998;11 (1 ):142–19. doi:10.1128/CMR.11.1.142.9457432
2. Ochoa TJ, Contreras CA. Enteropathogenic Escherichia coli infection in children. Curr Opin Infect Dis. 2011;24 (5 ):478–483. doi:10.1097/QCO.0b013e32834a8b8b.21857511
3. Kaur P, Dudeja PK. Pathophysiology of enteropathogenic Escherichia coli-induced diarrhea. Newborn. 2023;2 (1 ):102–113. doi:10.5005/jp-journals-11002-0056.37388762
4. Silberger DJ, Zindl CL, Weaver CT. Citrobacter rodentium: a model enteropathogen for understanding the interplay of innate and adaptive components of type 3 immunity. Mucosal Immunol. 2017;10 (5 ):1108–1117. doi:10.1038/mi.2017.47.28612839
5. Slater SL, Sagfors AM, Pollard DJ, Ruano-Gallego D, Frankel G. The type III secretion system of pathogenic Escherichia coli. Curr Top Microbiol Immunol. 2018;416 :51–72.30088147
6. Sanchez-Garrido J, Ruano-Gallego D, Choudhary JS, Frankel G. The type III secretion system effector network hypothesis. Trends Microbiol. 2021;30 (6 ):524–533. doi:10.1016/j.tim.2021.10.007.34840074
7. Miner MV, Rauch I, Richardson AR. Why put yourself on a pedestal? The pathogenic role of the A/E pedestal. Infect Immun. 2024; e0048923. doi:10.1128/iai.00489-23.38591884
8. El Qaidi S, Wu M, Zhu C, Hardwidge PR. Salmonella, E. coli, and citrobacter type III secretion system effector proteins that alter host innate immunity. Adv Exp Med Biol. 2019;1111 :205–218.30411307
9. Shenoy AR, Furniss RCD, Goddard PJ, Clements A. Modulation of host cell processes by T3SS effectors. Curr Top Microbiol Immunol. 2018;416 :73–115.30178263
10. Lee YT, Senturk M, Guan Y, Wang MC. Bacteria–organelle communication in physiology and disease. J Cell Biol. 2024;223 (7 ):223. doi:10.1083/jcb.202310134.
11. Ritchie JM, Waldor MK. The locus of enterocyte effacement-encoded effector proteins all promote enterohemorrhagic Escherichia coli pathogenicity in infant rabbits. Infect Immun. 2005;73 (3 ):1466–1474. doi:10.1128/IAI.73.3.1466-1474.2005.15731044
12. Wong AR, Pearson JS, Bright MD, Munera D, Robinson KS, Lee SF, Frankel G, Hartland EL. Enteropathogenic and enterohaemorrhagic Escherichia coli: even more subversive elements. Mol Microbiol. 2011;80 (6 ):1420–1438. doi:10.1111/j.1365-2958.2011.07661.x.21488979
13. Wong AR, Raymond B, Collins JW, Crepin VF, Frankel G. The enteropathogenic E. coli effector EspH promotes actin pedestal formation and elongation via wasp-interacting protein (WIP). Cellular Microbiol. 2012;14 (7 ):1051–1070. doi:10.1111/j.1462-5822.2012.01778.x.
14. Wong AR, Clements A, Raymond B, Crepin VF, Frankel G, Bagnoli F, Rappuoli R. The interplay between the Escherichia coli rho guanine nucleotide exchange factor effectors and the mammalian RhoGEF inhibitor EspH. MBio. 2012;3 (1 ):3. doi:10.1128/mBio.00250-11.
15. Tu X, Nisan I, Yona C, Hanski E, Rosenshine I. EspH, a new cytoskeleton-modulating effector of enterohaemorrhagic and enteropathogenic Escherichia coli. Mol Microbiol. 2003;47 (3 ):595–606. doi:10.1046/j.1365-2958.2003.03329.x.12535063
16. Dong N, Liu L, Shao F. A bacterial effector targets host DH-PH domain RhoGEFs and antagonizes macrophage phagocytosis. Embo J. 2010;29 (8 ):1363–1376. doi:10.1038/emboj.2010.33.20300064
17. Ramachandran RP, Nandi I, Haritan N, Zlotkin-Rivkin E, Keren Y, Danieli T, Lebendiker M, Melamed-Book N, Breuer W, Reichmann D, et al. EspH interacts with the host active Bcr related (ABR) protein to suppress RhoGTPases. Gut Microbes. 2022;14 (1 ):2130657. doi:10.1080/19490976.2022.2130657.36219160
18. Roxas JL, Monasky RC, Roxas BAP, Agellon AB, Mansoor A, Kaper JB, Vedantam G, Viswanathan VK. Enteropathogenic Escherichia coli EspH-mediated rho GTPase inhibition results in desmosomal perturbations. Cell Mol Gastroenterol Hepatol. 2018;6 (2 ):163–180. doi:10.1016/j.jcmgh.2018.04.007.30003123
19. Ramachandran RP, Vences-Catalan F, Wiseman D, Zlotkin-Rivkin E, Shteyer E, Melamed-Book N, Rosenshine I, Levy S, Aroeti B, et al. EspH suppresses Erk by spatial segregation from CD81 Tetraspanin Microdomains. Infect Immun. 2018;86 (10 ). doi:10.1128/IAI.00303-18.
20. Roxas JL, Ramamurthy S, Cocchi K, Rutins I, Harishankar A, Agellon A, Wilbur JS, Sylejmani G, Vedantam G, Viswanathan VK, et al. Enteropathogenic Escherichia coli regulates host-cell mitochondrial morphology. Gut Microbes. 2022;14 (1 ):2143224. doi:10.1080/19490976.2022.2143224.36476073
21. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 2001;2 (2 ):107–117. doi:10.1038/35052055.11252952
22. Herve JC, Bourmeyster N. Rab GTPases, master controllers of eukaryotic trafficking. Small GTPases. 2018;9 (1–2 ):1–4. doi:10.1080/21541248.2018.1428853.29368995
23. Hutagalung AH, Novick PJ. Role of rab GTPases in membrane traffic and cell physiology. Physiol Rev. 2011;91 (1 ):119–149. doi:10.1152/physrev.00059.2009.21248164
24. Novick P. Regulation of membrane traffic by Rab GEF and GAP cascades. Small GTPases. 2016;7 (4 ):252–256. doi:10.1080/21541248.2016.1213781.27427966
25. Pfeffer S, Aivazian D. Targeting Rab GTPases to distinct membrane compartments. Nat Rev Mol Cell Biol. 2004;5 (11 ):886–896. doi:10.1038/nrm1500.15520808
26. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science. 2001;294 (5545 ):1299–1304. doi:10.1126/science.1062023.11701921
27. Khan AR. Oligomerization of rab/effector complexes in the regulation of vesicle trafficking. Prog Mol Biol Transl Sci. 2013;117 :579–614.23663983
28. Gillingham AK, Sinka R, Torres IL, Lilley KS, Munro S. Toward a comprehensive map of the effectors of rab GTPases. Dev Cell. 2014;31 (3 ):358–373. doi:10.1016/j.devcel.2014.10.007.25453831
29. Spano S, Galan JE. Taking control: hijacking of rab GTPases by intracellular bacterial pathogens. Small GTPases. 2018;9 (1–2 ):182–191. doi:10.1080/21541248.2017.1336192.28632996
30. Stein MP, Muller MP, Wandinger-Ness A. Bacterial pathogens commandeer Rab GTPases to establish intracellular niches. Traffic. 2012;13 (12 ):1565–1588. doi:10.1111/tra.12000.22901006
31. Sherwood RK, Roy CR. A Rab-centric perspective of bacterial pathogen-occupied vacuoles. Cell Host & Microbe. 2013;14 (3 ):256–268. doi:10.1016/j.chom.2013.08.010.24034612
32. Dubreuil R, Segev N. Bringing host-cell takeover by pathogenic bacteria to center stage. Cell Logist. 2011;1 (4 ):120–124. doi:10.4161/cl.1.4.18984.22279609
33. Gan J, Scott NE, Newson JPM, Wibawa RR, Wong Fok Lung T, Pollock GL, Ng GZ, van Driel I, Pearson JS, Hartland EL, et al. The salmonella effector SseK3 targets small Rab GTPases. Front Cell Infect Microbiol. 2020;10 :419. doi:10.3389/fcimb.2020.00419.32974215
34. Spano S, Gao X, Hannemann S, Lara-Tejero M, Galan JE. A bacterial pathogen targets a host Rab-family GTPase defense pathway with a GAP. Cell Host & Microbe. 2016;19 (2 ):216–226. doi:10.1016/j.chom.2016.01.004.26867180
35. Mousnier A, Schroeder GN, Stoneham CA, So EC, Garnett JA, Yu L, Matthews SJ, Choudhary JS, Hartland EL, Frankel G, et al. A new method to determine in vivo interactomes reveals binding of the Legionella pneumophila effector PieE to multiple rab GTPases. MBio. 2014;5 (4 ). doi:10.1128/mBio.01148-14.
36. Goody PR, Heller K, Oesterlin LK, Muller MP, Itzen A, Goody RS. Reversible phosphocholination of Rab proteins by Legionella pneumophila effector proteins. Embo J. 2012;31 (7 ):1774–1784. doi:10.1038/emboj.2012.16.22307087
37. Boddy KC, Zhu H, D’Costa VM, Xu C, Beyrakhova K, Cygler M, Grinstein S, Coyaud E, Laurent EMN, St-Germain J, et al. Salmonella effector SopD promotes plasma membrane scission by inhibiting Rab10. Nat Commun. 2021;12 (1 ):4707. doi:10.1038/s41467-021-24983-z.34349110
38. Schoebel S, Cichy AL, Goody RS, Itzen A. Protein LidA from Legionella is a Rab GTPase supereffector. Proc Natl Acad Sci USA. 2011;108 (44 ):17945–17950. doi:10.1073/pnas.1113133108.22011575
39. Cheng W, Yin K, Lu D, Li B, Zhu D, Chen Y, Zhang H, Xu S, Chai J, Gu L, et al. Structural insights into a unique Legionella pneumophila effector LidA recognizing both GDP and GTP bound Rab1 in their active state. PLOS Pathog. 2012;8 (3 ):e1002528. doi:10.1371/journal.ppat.1002528.22416225
40. Lian H, Jiang K, Tong M, Chen Z, Liu X, Galan JE, Gao X. The Salmonella effector protein SopD targets Rab8 to positively and negatively modulate the inflammatory response. Nat Microbiol. 2021;6 (5 ):658–671. doi:10.1038/s41564-021-00866-3.33603205
41. Savitskiy S, Itzen A. SopD from Salmonella specifically inactivates Rab8. Biochimica et biophysica acta proteins and proteomics. Biochim Et Biophys Acta (BBA) - Proteins Proteomics. 2021;1869 (8 ):140661. doi:10.1016/j.bbapap.2021.140661.
42. Ingmundson A, Delprato A, Lambright DG, Roy CR. Legionella pneumophila proteins that regulate Rab1 membrane cycling. Nature. 2007;450 (7168 ):365–369. doi:10.1038/nature06336.17952054
43. Machner MP, Isberg RR. A bifunctional bacterial protein links GDI displacement to Rab1 activation. Science. 2007;318 (5852 ):974–977. doi:10.1126/science.1149121.17947549
44. Murata T, Delprato A, Ingmundson A, Toomre DK, Lambright DG, Roy CR. The legionella pneumophila effector protein DrrA is a Rab1 guanine nucleotide-exchange factor. Nat Cell Biol. 2006;8 (9 ):971–977. doi:10.1038/ncb1463.16906144
45. Muller MP, Peters H, Blumer J, Blankenfeldt W, Goody RS, Itzen A. The Legionella effector protein DrrA AMPylates the membrane traffic regulator Rab1b. Science. 2010;329 (5994 ):946–949. doi:10.1126/science.1192276.20651120
46. Neunuebel MR, Chen Y, Gaspar AH, Backlund PS Jr., Yergey A, Machner MP. De-AMPylation of the small GTPase Rab1 by the pathogen Legionella pneumophila. Science. 2011;333 (6041 ):453–456. doi:10.1126/science.1207193.21680813
47. Tan Y, Luo ZQ. Legionella pneumophila SidD is a deAmpylase that modifies Rab1. Nature. 2011;475 (7357 ):506–509. doi:10.1038/nature10307.21734656
48. Chen Y, Machner MP. Targeting of the small GTPase Rab6A′ by the Legionella pneumophila Effector LidA. Infect Immun. 2013;81 (6 ):2226–2235. doi:10.1128/IAI.00157-13.23569112
49. Ramachandran RP, Spiegel C, Keren Y, Danieli T, Melamed-Book N, Pal RR, Zlotkin-Rivkin E, Rosenshine I, Aroeti B, et al. Mitochondrial targeting of the enteropathogenic Escherichia coli map triggers calcium mobilization, ADAM10-MAP kinase signaling, and host cell apoptosis. MBio. 2020;11 (5 ):11. doi:10.1128/mBio.01397-20.
50. Shtuhin-Rahav R, Olender A, Zlotkin-Rivkin E, Bouman EA, Danieli T, Nir-Keren Y, Weiss AM, Nandi I, Aroeti B. Enteropathogenic E. coli infection co-elicits lysosomal exocytosis and lytic host cell death. MBio. 2023;14 (6 ):e0197923. doi:10.1128/mbio.01979-23.38038448
51. Kassa EG, Zlotkin-Rivkin E, Friedman G, Ramachandran RP, Melamed-Book N, Weiss AM, Belenky M, Reichmann D, Breuer W, Pal RR, et al. Enteropathogenic Escherichia coli remodels host endosomes to promote endocytic turnover and breakdown of surface polarity. PLOS Pathog. 2019;15 (6 ):e1007851. doi:10.1371/journal.ppat.1007851.31242273
52. Haritan N, Bouman EA, Nandi I, Shtuhin-Rahav R, Zlotkin-Rivkin E, Danieli T, Melamed-Book N, Nir-Keren Y, Aroeti B. Topology and function of translocated EspZ. MBio. 2023; e0075223. doi:10.1128/mbio.00752-23.37341483
53. Shinde SR, Maddika S. Post translational modifications of Rab GTPases. Small GTPases. 2018;9 (1–2 ):49–56. doi:10.1080/21541248.2017.1299270.28426288
54. Lan Y, Sullivan PM, Hu F. SMCR8 negatively regulates AKT and MTORC1 signaling to modulate lysosome biogenesis and tissue homeostasis. Autophagy. 2019;15 (5 ):871–885. doi:10.1080/15548627.2019.1569914.30696333
55. Wang B, He W, Prosseda PP, Li L, Kowal TJ, Alvarado JA, Wang Q, Hu Y, Sun Y. OCRL regulates lysosome positioning and mTORC1 activity through SSX2IP-mediated microtubule anchoring. EMBO Rep. 2021;22 (7 ):e52173. doi:10.15252/embr.202052173.33987909
56. Li L, Kim E, Yuan H, Inoki K, Goraksha-Hicks P, Schiesher RL, Neufeld TP, Guan K-L. Regulation of mTORC1 by the Rab and Arf GTPases. J Biol Chem. 2010;285 (26 ):19705–19709. doi:10.1074/jbc.C110.102483.20457610
57. Sun Y, Bilan PJ, Liu Z, Klip A. Rab8A and Rab13 are activated by insulin and regulate GLUT4 translocation in muscle cells. Proc Natl Acad Sci USA. 2010;107 (46 ):19909–19914. doi:10.1073/pnas.1009523107.21041651
58. Wu B, Liu DA, Guan L, Myint PK, Chin L, Dang H, Xu Y, Ren J, Li T, Yu Z, et al. Stiff matrix induces exosome secretion to promote tumour growth. Nat Cell Biol. 2023;25 (3 ):415–424. doi:10.1038/s41556-023-01092-1.36797475
59. Walia V, Cuenca A, Vetter M, Insinna C, Perera S, Lu Q, Ritt DA, Semler E, Specht S, Stauffer J, et al. Akt regulates a Rab11-effector switch required for ciliogenesis. Dev Cell. 2019;50 (2 ):229–246.e7. doi:10.1016/j.devcel.2019.05.022.31204173
60. Luo L, Wall AA, Yeo JC, Condon ND, Norwood SJ, Schoenwaelder S, Chen KW, Jackson S, Jenkins BJ, Hartland EL, et al. Rab8a interacts directly with PI3Kγ to modulate TLR4-driven PI3K and mTOR signalling. Nat Commun. 2014;5 (1 ):4407. doi:10.1038/ncomms5407.25022365
61. Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15 (10 ):599–614. doi:10.1038/nri3901.26403194
62. Wall AA, Luo L, Hung Y, Tong SJ, Condon ND, Blumenthal A, Sweet MJ, Stow JL. Small GTPase Rab8a-recruited phosphatidylinositol 3-kinase γ regulates signaling and cytokine outputs from endosomal toll-like receptors. J Biol Chem. 2017;292 (11 ):4411–4422. doi:10.1074/jbc.M116.766337.28130450
63. Encarnacao M, Espada L, Escrevente C, Mateus D, Ramalho J, Michelet X, Santarino I, Hsu VW, Brenner MB, Barral DC, et al. A Rab3a-dependent complex essential for lysosome positioning and plasma membrane repair. J Cell Biol. 2016;213 (6 ):631–640. doi:10.1083/jcb.201511093.27325790
64. Vieira OV. Rab3a and Rab10 are regulators of lysosome exocytosis and plasma membrane repair. Small GTPases. 2018;9 (4 ):349–351. doi:10.1080/21541248.2016.1235004.27687479
65. Escrevente C, Bento-Lopes L, Ramalho JS, Barral DC. Rab11 is required for lysosome exocytosis through the interaction with Rab3a, Sec15 and GRAB. J Cell Sci. 2021;134 (11 ):134. doi:10.1242/jcs.246694.
66. Salomon D, Guo Y, Kinch LN, Grishin NV, Gardner KH, Orth K. Effectors of animal and plant pathogens use a common domain to bind host phosphoinositides. Nat Commun. 2013;4 (1 ):2973. doi:10.1038/ncomms3973.24346350
67. Posor Y, Jang W, Haucke V. Phosphoinositides as membrane organizers. Nat Rev Mol Cell Biol. 2022;23 (12 ):797–816. doi:10.1038/s41580-022-00490-x.35589852
68. Sason H, Milgrom M, Weiss AM, Melamed-Book N, Balla T, Grinstein S, Backert S, Rosenshine I, Aroeti B. Enteropathogenic Escherichia coli subverts phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate upon epithelial cell infection. Mol Biol Cell. 2009;20 (1 ):544–555. doi:10.1091/mbc.e08-05-0516.18987340
69. Campellone KG. Phosphoinositides influence pathogen surfing: EPEC rights the SHIP. Cell Host & Microbe. 2010;7 (1 ):1–2. doi:10.1016/j.chom.2009.12.006.20114020
70. Smith K, Humphreys D, Hume PJ, Koronakis V. Enteropathogenic Escherichia coli recruits the cellular inositol phosphatase SHIP2 to regulate actin-pedestal formation. Cell Host & Microbe. 2010;7 (1 ):13–24. doi:10.1016/j.chom.2009.12.004.20114025
71. Wong AR, Raymond B, Collins JW, Crepin VF, Frankel G. The enteropathogenic E. coli effector EspH promotes actin pedestal formation and elongation via wasp-interacting protein (WIP). Cell Microbiol. 2012;14 (7 ):1051–1070. doi:10.1111/j.1462-5822.2012.01778.x.22372637
72. Hong Z, Pedersen NM, Wang L, Torgersen ML, Stenmark H, Raiborg C. PtdIns3P controls mTORC1 signaling through lysosomal positioning. J Cell Biol. 2017;216 (12 ):4217–4233. doi:10.1083/jcb.201611073.29030394
73. Puertollano R. mTOR and lysosome regulation. F1000Prime Rep. 2014;6 :52. doi:10.12703/P6-52.25184042
74. Mutvei AP, Nagiec MJ, Hamann JC, Kim SG, Vincent CT, Blenis J. Rap1-GTPases control mTORC1 activity by coordinating lysosome organization with amino acid availability. Nat Commun. 2020;11 (1 ):1416. doi:10.1038/s41467-020-15156-5.32184389
75. Jean S, Kiger AA. Coordination between RAB GTPase and phosphoinositide regulation and functions. Nat Rev Mol Cell Biol. 2012;13 (7 ):463–470. doi:10.1038/nrm3379.22722608
76. Viaud J, Gaits-Iacovoni F, Payrastre B. Regulation of the DH–PH tandem of guanine nucleotide exchange factor for Rho GTPases by phosphoinositides. Adv Biol Regul. 2012;52 (2 ):303–314. doi:10.1016/j.jbior.2012.04.001.22781744
77. Croise P, Estay-Ahumada C, Gasman S, Ory S. Rho GTPases, phosphoinositides, and actin: a tripartite framework for efficient vesicular trafficking. Small GTPases. 2014;5 (2 ):e29469. doi:10.4161/sgtp.29469.24914539
78. Goosney DL, Celli J, Kenny B, Finlay BB, Sansonetti PJ. Enteropathogenic Escherichia coli inhibits phagocytosis. Infect Immun. 1999;67 (2 ):490–495. doi:10.1128/IAI.67.2.490-495.1999.9916050
79. Humphreys D, Singh V, Koronakis V. Inhibition of WAVE regulatory complex activation by a bacterial virulence effector counteracts Pathogen Phagocytosis. Cell Rep. 2016;17 (3 ):697–707. doi:10.1016/j.celrep.2016.09.039.27732847
80. Celli J, Olivier M, Finlay BB. Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways. Embo J. 2001;20 (6 ):1245–1258. doi:10.1093/emboj/20.6.1245.11250891
